Clinical Trials Logo

Filter by:
  • No longer available  
  • Page [1]
NCT ID: NCT03523338 No longer available - Prostatic Neoplasms Clinical Trials

An Expanded Access Protocol for Apalutamide Treatment of Participants With Non-Metastatic Castration-Resistant Prostate Cancer

Start date: n/a
Phase:
Study type: Expanded Access

The purpose of this study is to collect additional safety data until apalutamide is commercially available for participants with non-metastatic castrate-resistant prostate cancer (NM-CRPC).

NCT ID: NCT02865109 No longer available - Clinical trials for Infantile-onset Spinal Muscular Atrophy

Expanded Access Program (EAP) for Nusinersen in Participants With Infantile-onset (Consistent With Type 1) Spinal Muscular Atrophy (SMA)

Start date: n/a
Phase:
Study type: Expanded Access

To provide access to nusinersen to eligible patients with Infantile-onset Spinal Muscular Atrophy (SMA) (consistent with Type 1) to address a high-unmet medical need.

NCT ID: NCT02142218 No longer available - Clinical trials for Stage III (Unresectable) or Stage IV Advanced Melanoma

Expanded Access Program With Nivolumab to Treat Melanoma

Checkmate 168
Start date: June 2014
Phase: N/A
Study type: Expanded Access

The purpose of this program is to provide treatment with nivolumab to subjects with Stage III or Stage IV advanced melanoma.

NCT ID: NCT01947608 No longer available - Clinical trials for Non-small Cell Lung Cancer (NSCLC)

Expanded Treatment Protocol With LDK378 in ALK(+) NSCLC

Start date: n/a
Phase:
Study type: Expanded Access

Novartis-sponsored, open-label, multi-center, interventional ETP to provide LDK378 to patients with ALK (+)NSCLC, who have been pre-treated with an ALK inhibitor; except in countries where ALK inhibitors are not approved or available. The protocol will further evaluate the safety of LDK378 in patients with ALK(+) NSCLC.

NCT ID: NCT01784562 No longer available - Clinical trials for Hypertension, Pulmonary

Riociguat in Patients With Chronic Thromboembolic Pulmonary Hypertension (CTEPH)

EAS
Start date: n/a
Phase: N/A
Study type: Expanded Access

The aim of the study is to assess safety, tolerability and clinical effects of different doses of riociguat in patients with inoperable Chronic Thromboembolic Pulmonary Hypertension (CTEPH) and who are not satisfactorily treated and cannot participate in any other CTEPH trial. In the US the study runs as an Expanded Access program under 21 CFR 312.320.